HOME >> BIOLOGY >> NEWS
Researchers discover gene causing deadly infantile form of genetic kidney disease

Identification of gene PKHD1 brings hope of cure to sufferers of autosomal recessive polycystic kidney disease

Kansas City, Mo. (February 6, 2002) Researchers at the Mayo Clinic have identified and fully characterized the gene that causes autosomal recessive polycystic kidney disease (ARPKD), raising hopes of a treatment and eventual cure for infants born with ARPKD. The Polycystic Kidney Disease (PKD) Foundation provided grants that led to the promising discovery of the PKHD1 gene, an effort aided by earlier work done at the Human Genome Project. The March 2002 issue of Nature Genetics will feature this breakthrough.

ARPKD is one of a group of polycystic kidney diseases that together make up the worlds most common life-threatening genetic disease, affecting 600,000 children and adults in the United States and 12.5 million people worldwide. In the U.S., more people have PKD than the combined number of those who have cystic fibrosis, muscular dystrophy, Downs syndrome, hemophilia, sickle cell anemia and Huntingtons disease. The disease affects people equally irrespective of age, race, gender, ethnicity, geographic location or socioeconomic status.

ARPKD, often referred to as infantile PKD, is a particularly lethal form of PKD resulting in the development of multiple fluid-filled cysts in the kidney and fibrosis in the liver. The disease is often associated with poor lung development and infant death. There is currently no treatment or cure for ARPKD, but the discovery of the ARPKD gene now provides researchers with a genetic road map for a functional understanding of how PKD progresses, and paves the way for gene testing, more conclusive diagnosis, and treatments to retard development of the disease.

Identifying the causative gene is a major step forward as the basic defect and progression of the disease can now be studied, said Peter C. Harris, Ph.D., of the Mayo Clinic and the lead researcher in the study. The
'"/>

Contact: Jim Guarnera
jguarner@hillandknowlton.com
212-885-0303
Hill and Knowlton
6-Feb-2002


Page: 1 2

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology:
Cached News: